David Powers
31Patents
10h-index
28Co-inventors
75Inventor score
Filing activity: Aug 11, 1992 → Feb 23, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5411873A | Process for producing heterologous polypeptides | Chemistry; Metallurgy | 38 | Expired |
| US7709610B2 | Therapeutic use of anti-CS1 antibodies | Chemistry; Metallurgy | 27 | Active |
| US5376544A | Enzymes for the production of 2-keto-L-gulonic acid | Chemistry; Metallurgy | 27 | Expired |
| US5795761A | Mutants of 2,5-diketo-D-gluconic acid (2,5-DKG) reductase A | Emerging Cross-Sectional Technologies | 23 | Expired |
| US7288248B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 18 | Expired |
| US9079953B2 | Anti-VEGF antibodies and their uses | Chemistry; Metallurgy | 17 | Active |
| US7276589B2 | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis | Chemistry; Metallurgy | 14 | Expired |
| US5583025A | Enzymes for the production of 2-keto-L-gulonic acid | Chemistry; Metallurgy | 13 | Expired |
| US10233258B2 | Bispecific binding proteins that bind CD40 and mesothelin | Chemistry; Metallurgy | 12 | Active |
| US5912161A | Enzymes for the production of 2-keto-L-gulonic acid | Chemistry; Metallurgy | 10 | Expired |
| US8633139B2 | Methods of screening complex protein libraries to identify altered properties | Chemistry; Metallurgy | 10 | Active |
| US7285268B2 | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis | Chemistry; Metallurgy | 10 | Expired |
| US5939315A | Process for producing heterologous polypeptides | Chemistry; Metallurgy | 9 | Expired |
| US8658175B2 | Anti-EGFR antibodies and their uses | Chemistry; Metallurgy | 9 | Active |
| US9315573B2 | Anti-TNF-alpha antibodies and their uses | Chemistry; Metallurgy | 8 | Active |
| US8937159B2 | Anti-HER2 antibodies and their uses | Chemistry; Metallurgy | 6 | Active |
| US8461306B2 | Therapeutic use of anti-CS1 antibodies | Chemistry; Metallurgy | 6 | Active |
| US8436146B2 | Therapeutic use of anti-CS1 antibodies | Chemistry; Metallurgy | 5 | Active |
| US8349330B2 | Therapeutic use of anti-CS1 antibodies | Chemistry; Metallurgy | 5 | Active |
| US8444980B2 | Therapeutic use of anti-CS1 antibodies | Chemistry; Metallurgy | 5 | Active |
| US7674883B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US7824678B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US7785816B2 | Antibodies against cancer antigen TMEFF2 and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US8017116B2 | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis | Chemistry; Metallurgy | 1 | Active |
| US8309084B2 | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.